Lab21 to market deCODE genetic tests for common diseases in UK
13 August 2008
Cambridge company Lab21 Limited has entered into a partnership with
Icelandic company deCODE genetics (Nasdaq:DCGN), to offer deCODE’s tests
for predisposition to a growing number of common diseases.
Lab21 offers molecular diagnostic services for disease
identification, disease predisposition and personalised medicine.
The licence allows Lab21 to offer its clients in the UK and Ireland
access to state-of-the-art new tests for type 2 diabetes, myocardial
infarction, atrial fibrillation, prostate cancer and glaucoma.
This agreement means Lab21 now has licences with three major genetic
test providers; deCODE, Myriad and PGxHealth, and is currently the only
service provider in Europe to offer such an extensive range.
deCODE, a biopharmaceutical company based in Reykjavik, Iceland, is
widely regarded as being the global leader in the development of tests
for validated genetic markers that confer risk of common diseases.
In addition, the license will allow Lab21 to offer a pipeline of new
tests as they are developed by deCODE, including one for increased risk
of oestrogen-positive breast cancer. All deCODE tests have been
validated in thousands of patients and controls from multiple
populations; have full regulatory approval; and will be handled through
Lab21’s clinical service laboratory in Cambridge.
Dr Berwyn Clarke, Chief Science and Development Officer at Lab21
said: “Genetic testing is becoming an increasingly important part of
medicine. In many patients, awareness of clinical predisposition can
provide critical early warnings of the possible development of disease
and vital pre-emptive and precautionary measures such as dietary
factors, detailed screening or pharmaceutical intervention can be
implemented. This is critical as we work to shift the focus of
healthcare from intervention to prevention. Our agreement with deCODE
will ensure clinicians can provide their patients with the most accurate
and timely information.”
Lab21’s range of genetic tests now includes tests for breast,
ovarian, skin and colorectal cancer, a comprehensive portfolio of tests
for cardiovascular disease and now, with deCODE’s tests for type 2
diabetes, prostate cancer and exfoliating glaucoma, the first ones in
new disease areas.
Graham Mullis, CEO of Lab21 added: “We are extremely pleased to have
completed this deal, as it ensures we are able to provide our customers
with the widest range of high quality genetic tests in Europe,
illustrating Lab21’s commitment to being a leading provider of cutting
Kari Stefansson, CEO of deCODE genetics, said: “We are very pleased
to have Lab21 offering our tests in the UK and Ireland. Lab21 knows the
market and has proven capabilities in marketing logistics and customer
service. We believe this partnership will enable us to better leverage
the potential of our growing product portfolio, reaching more physicians
and healthcare systems and raising the profile of our innovative tests
in the UK and Ireland.”